Lu X, Baudouin S V, Gillespie J I, Anderson J J, Dickinson A M
Haematological Sciences, University of Newcastle upon Tyne, Newcastle upon Tyne, NE2 4HH, UK.
Cytotherapy. 2007;9(3):292-300. doi: 10.1080/14653240701247853.
CD133 is a newly developed hematopoietic stem cell marker but little is known about its function. Whether CD133(+) cell selection provides any advantage over CD34(+) selection for hematopoietic stem cell isolation and transplantation is unclear. The present study compared colony formation and endothelial cell differentiation of these two cell types from umbilical cord blood (UCB).
Mononuclear cells from the same UCB samples were used for both CD133(+) and CD34(+) cell selection. Cells with 97.1% purity were incubated in semi-solid culture medium containing stem cell growth factor (SCGF) and G-CSF or erythropoietin (EPO). Purified cells were also cultured in M199 containing vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and insulin-like growth factor-1 (IGF-1).
CD34(+) and CD133(+) cells produced similar numbers of CFU-GM colonies (median 43.25 and 30.5, respectively; P>0.2). However, a greater than four-fold difference in BFU-E colony formation was observed from CD34(+) cells compared with CD133(+) cells (median 35 and 8, respectively; P<0.04). CD34(+) cells gave rise to endothelial-like cells when stimulated with VEGF, bFGF and IGF-1. CD133(+) cells were unable produce this cell type under the same conditions.
CD133(+) cells produced smaller BFU-E colonies and were unable to differentiate into mature endothelial cells. CD34(+) cells contained endothelial progenitors that could differentiate into mature cells of this lineage. Based on these data, it appears that CD133 offers no distinct advantage over CD34 as a selective marker for immunoaffinity-based isolation of hematopoietic stem cells and endothelial progenitor cells.
CD133是一种新发现的造血干细胞标志物，但其功能鲜为人知。CD133(+)细胞选择在造血干细胞分离和移植方面是否比CD34(+)选择具有任何优势尚不清楚。本研究比较了脐带血（UCB）中这两种细胞类型的集落形成和内皮细胞分化情况。
使用来自相同UCB样本的单核细胞进行CD133(+)和CD34(+)细胞选择。将纯度为97.1%的细胞在含有干细胞生长因子（SCGF）和G-CSF或促红细胞生成素（EPO）的半固体培养基中孵育。纯化后的细胞也在含有血管内皮生长因子（VEGF）、碱性成纤维细胞生长因子（bFGF）和胰岛素样生长因子-1（IGF-1）的M199中培养。
CD34(+)和CD133(+)细胞产生的CFU-GM集落数量相似（中位数分别为43.25和30.5；P>0.2）。然而，与CD133(+)细胞相比，CD34(+)细胞形成的BFU-E集落差异超过四倍（中位数分别为35和8；P<0.04）。当用VEGF、bFGF和IGF-1刺激时，CD34(+)细胞可产生内皮样细胞。在相同条件下，CD133(+)细胞无法产生这种细胞类型。
CD133(+)细胞产生的BFU-E集落较小，且无法分化为成熟的内皮细胞。CD34(+)细胞含有可分化为该谱系成熟细胞的内皮祖细胞。基于这些数据，作为基于免疫亲和的造血干细胞和内皮祖细胞分离的选择标志物，CD133似乎并不比CD34具有明显优势。
